Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor “What This Means” Segment

Moleculin Reaches 45-Subject Enrollment Milestone in MIRACLE Trial

Moleculin Biotech announced that its CEO, Walter Klemp, highlighted the enrollment of the 45th subject in the pivotal Phase 2B/3 MIRACLE trial. This trial evaluates Annamycin in combination with cytarabine (AnnAraC) for relapsed or refractory acute myeloid leukemia (R/R AML). This milestone triggers the final preparations for the trial’s interim 45-subject data unblinding, which is on track for mid-2026 and is considered a potentially defining inflection point for the company. The announcement was made during a Virtual Investor “What This Means” segment.

• The MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) trial is a pivotal, adaptive design Phase 3 study investigating Annamycin in combination with cytarabine (AnnAraC) for adult subjects with relapsed or refractory acute myeloid leukemia. This trial follows a successful Phase 1B/2 study (MB-106), and with FDA input, the company believes it has substantially de-risked the development pathway for potential approval.
• The enrollment of the 45th subject is a critical milestone, initiating the final phase of preparation for the trial’s interim data unblinding. This unblinding, expected in mid-2026, is anticipated to be a defining inflection point for Moleculin Biotech, providing crucial insights into the efficacy and safety profile of AnnAraC in R/R AML.
• Annamycin is a next-generation anthracycline designed to overcome multidrug resistance and avoid the cardiotoxicity common with other anthracyclines. Beyond R/R AML, Annamycin is also in development for soft tissue sarcoma lung metastases. Moleculin's pipeline further includes WP1066, an Immune/Transcription Modulator for brain tumors and pancreatic cancer, and WP1122 for pathogenic viruses and certain cancer indications.

Unpacking the MIRACLE Trial Design for R/R AML

The clinical trial landscape for relapsed/refractory AML encompasses diverse therapeutic approaches, from novel combination regimens to salvage chemotherapy protocols. Recent studies have focused on optimizing treatment selection through comparative effectiveness research and identifying prognostic factors that influence therapeutic outcomes.

Annamycin's Differentiated Safety Profile in R/R AML

Preclinical toxicology studies demonstrate that while free annamycin exhibits approximately twice the acute toxicity of doxorubicin in mice (LD50: 8.8 mg/kg versus 19.9 mg/kg), liposomal encapsulation significantly improves its safety profile by reducing toxicity 2-fold. The primary dose-limiting toxicity identified was granulocytopenia, which was more profound than that observed with equitoxic doses of doxorubicin. However, this selective myelotoxicity may represent a favorable characteristic for hematologic malignancy treatment where bone marrow suppression can contribute to therapeutic efficacy.

The most clinically significant safety advantage of liposomal annamycin appears to be its substantially reduced cardiotoxicity compared to doxorubicin in chronic dosing studies. Weekly administration studies revealed markedly lower cumulative toxicity with liposomal annamycin, as evidenced by reduced mortality and better preservation of body weight compared to doxorubicin. Additionally, liposomal annamycin demonstrated decreased vesicant potential following intradermal administration, suggesting reduced risk of extravasation injury during clinical use.

Formulation optimization studies indicate that liposome characteristics significantly influence annamycin's toxicity profile. Reduction of liposome size from 1.6 to 0.03 microns decreased subacute toxicity by 2-fold, while entrapment in multilamellar vesicles resulted in 20% lower cardiac exposure. Safety validation in beagle dogs showed excellent tolerability at the mouse-equivalent LD10 dose (1.4 mg/kg) with no observable side effects or changes in hematological or biochemical parameters, supporting the progression to Phase I clinical trials with a starting dose of one-tenth the LD10.

Navigating the Treatment Challenges in Relapsed/Refractory AML

Relapsed and refractory acute myeloid leukemia presents formidable treatment challenges that have persisted despite decades of therapeutic advances. Current treatment approaches face fundamental limitations including drug resistance mechanisms, treatment-related toxicities, and suboptimal clinical outcomes that continue to result in poor patient prognosis.

• Drug resistance and high relapse rates remain the predominant challenges in AML treatment, with limited clinical measures available for refractory disease beyond palliative care

• Conventional chemotherapy limitations include serious side effects, high recurrence rates, and development of drug resistance, resulting in unsatisfactory outcomes due to drug toxicity and off-target effects

• Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is frequently limited by treatment-related toxicity, restricting its clinical application in many patients

• Donor lymphocyte infusion (DLI) demonstrates poor efficacy with overall remission rates of only 15-42%, 2-year overall survival of approximately 15-20%, and high incidence (40-60%) of treatment-related graft-versus-host disease

• Hypomethylating agents such as azacitidine and decitabine face significant challenges with relapse and therapeutic resistance despite their ability to reverse abnormal DNA methylation

• Leukemia stem cells and bone marrow microenvironment changes mediated by mesenchymal stem cells contribute substantially to treatment resistance and disease relapse

• Targeted therapy limitations include marginal effects of single agents, significant inter-patient variability, increased toxicities when combined with other agents, and continued occurrence of drug resistance

• Implementation barriers for novel targeted therapies include high costs, limited availability, and uncertain clinical relevance of newly identified biomarkers requiring further validation

Annamycin's Pivotal AML Milestone: High Stakes for Mid-2026 Unblinding

The recent announcement from Moleculin Biotech regarding the enrollment of the 45th subject in its pivotal Phase 2B/3 MIRACLE trial for Annamycin in relapsed or refractory acute myeloid leukemia (R/R AML) marks a critical juncture for the company and the broader oncology landscape. This milestone sets the stage for the highly anticipated interim data unblinding in mid-2026, an event explicitly highlighted as a potentially defining inflection point.

For Moleculin, the strategic implications are substantial. Positive interim data could fundamentally reshape the company's trajectory, potentially leading to:

• A significant boost in company valuation and investor confidence, attracting further capital or strategic partnerships.

• Acceleration of the drug's regulatory pathway, possibly qualifying for expedited review given the high unmet need in R/R AML.

• Establishment of Annamycin as a novel therapeutic option, carving out a distinct market position in a challenging indication where effective treatments are scarce.

However, this pivotal moment is not without its inherent risks. The binary nature of clinical trial outcomes means that negative or inconclusive interim data could significantly de-risk the program, potentially leading to delays or even discontinuation. Furthermore, while the event details highlight Annamycin's potential, the absence of specific clinical or scientific context for this particular drug in the broader published literature suggests a need for the interim data to clearly demonstrate a differentiated efficacy and safety profile against existing or emerging therapies. Finally, the reliance on a mid-2026 timeline for this critical data unblinding introduces a dependency risk; any unforeseen delays in trial execution or data analysis could impact investor sentiment and the company's strategic momentum.

The common use of the 'MIRACLE' trial identifier across various indications, as seen in other published studies, also underscores the importance of clear and precise communication from Moleculin Biotech to ensure their specific Annamycin trial stands out amidst the broader scientific discourse. As mid-2026 approaches, the oncology community will be keenly watching for these results, which hold the potential to redefine treatment strategies for R/R AML and significantly impact Moleculin's future.